BioArctic Receives a New Patent for Blood-Brain Barrier Delivery Technology in the US

STOCKHOLM, November 14, 2022 /PRNewswire/ — BioArctic AB (ed.) (Nasdaq Stockholm: BIOA B) announced today that the United States Patent and Trademark Office (USPTO) has granted BioArctic a new platform patent for a technology to deliver biopharmaceuticals across the blood-brain barrier. The patent, which is part of the company’s Brain Transporter patent portfolio, is effective on November 15, 2022and expire in 2037.

The blood-brain barrier protects the brain from foreign substances by restricting the passage of these substances into the brain. The patented technology (US Patent No. 11,498,974) was developed to facilitate the transport of biopharmaceuticals across this barrier, potentially improving drug efficacy.

“We are pleased that the US Patent and Trademark Office has granted this new patent. Improved delivery of biopharmaceuticals across the blood-brain barrier may result in improved efficacy and fewer side effects in current and future treatments for brain diseases,” says he Gunilla OsswaldCEO, BioArctic.

The information has been approved for publication by the agency of the contacts below November 14, 2022at 08:00 CET.

For more information please contact:

Gunilla OsswaldCHAIRMAN
E-mail: [email protected]e
Telephone: +46 8 695 69 30

Oscar BossonVP Communications and IR
E-mail: [email protected]
Telephone: +46 70 410 71 80

About BioArctic AB

BioArctic AB (publ) is a Swedish, research-based biopharmaceutical company focused on disease-modifying treatments for neurodegenerative diseases such as Alzheimer’s, Parkinson’s and ALS. BioArctic focuses on innovative treatments in areas of high unmet medical need. The company was founded in 2003 based on innovative research by University of Uppsala, Sweden. Collaborations with universities are of great importance for the company together with its strategically important global partner Eisai in Alzheimer’s disease. The project portfolio is a combination of fully funded projects, carried out in partnership with global pharmaceutical companies, and innovative in-house projects with significant market and out-licensing potential. BioArctic’s Class B shares are listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, visit

The following files are available for download:

SOURCE BioArctic


Leave a Reply

Your email address will not be published. Required fields are marked *